do you know this treatment, CAR t cells?

This topic has 18 replies, 4 voices, and was last updated 10 years, 7 months ago by Mat.

Post

- September 20, 2014 at 11:07 am
- Quote
jualonso
Participant
Hi folks,

I would like to know if some of you have heard about this treatment and if is the same as TIL or something little different.

http://www.medscape.com/viewarticle/831551

Thanks for your response

Jualonso

Viewing 14 reply threads

Replies

- - September 20, 2014 at 12:37 pm
  - Quote
  Sheepsandcows
  Participant
  Your post caught my interest and this is what i found on a very recent link http://www.fiercebiotech.com/story/memorial-sloan-kettering-hits-brakes-engineered-t-cell-cancer-study/2014-04-06
  
  Hope it helps
- - September 20, 2014 at 12:37 pm
  - Quote
  Sheepsandcows
  Participant
  Your post caught my interest and this is what i found on a very recent link http://www.fiercebiotech.com/story/memorial-sloan-kettering-hits-brakes-engineered-t-cell-cancer-study/2014-04-06
  
  Hope it helps
- - September 20, 2014 at 12:37 pm
  - Quote
  Sheepsandcows
  Participant
  Your post caught my interest and this is what i found on a very recent link http://www.fiercebiotech.com/story/memorial-sloan-kettering-hits-brakes-engineered-t-cell-cancer-study/2014-04-06
  
  Hope it helps
- - September 20, 2014 at 12:37 pm
  - Quote
  Sheepsandcows
  Participant
  Your post caught my interest and this is what i found on a very recent link http://www.fiercebiotech.com/story/memorial-sloan-kettering-hits-brakes-engineered-t-cell-cancer-study/2014-04-06
  
  Hope it helps
- - September 20, 2014 at 12:37 pm
  - Quote
  Sheepsandcows
  Participant
  Your post caught my interest and this is what i found on a very recent link http://www.fiercebiotech.com/story/memorial-sloan-kettering-hits-brakes-engineered-t-cell-cancer-study/2014-04-06
  
  Hope it helps
- - September 20, 2014 at 12:37 pm
  - Quote
  Sheepsandcows
  Participant
  Your post caught my interest and this is what i found on a very recent link http://www.fiercebiotech.com/story/memorial-sloan-kettering-hits-brakes-engineered-t-cell-cancer-study/2014-04-06
  
  Hope it helps
- - September 20, 2014 at 2:07 pm
  - Quote
  Sheepsandcows
  Participant
  Your post caught my interest and this is what i found on a very recent link http://www.fiercebiotech.com/story/memorial-sloan-kettering-hits-brakes-engineered-t-cell-cancer-study/2014-04-06
  
  Hope it helps
- - September 20, 2014 at 2:07 pm
  - Quote
  Sheepsandcows
  Participant
  Your post caught my interest and this is what i found on a very recent link http://www.fiercebiotech.com/story/memorial-sloan-kettering-hits-brakes-engineered-t-cell-cancer-study/2014-04-06
  
  Hope it helps
- - September 20, 2014 at 2:07 pm
  - Quote
  Sheepsandcows
  Participant
  Your post caught my interest and this is what i found on a very recent link http://www.fiercebiotech.com/story/memorial-sloan-kettering-hits-brakes-engineered-t-cell-cancer-study/2014-04-06
  
  Hope it helps
- - September 20, 2014 at 3:46 pm
  - Quote
  JerryfromFauq
  Participant
  http://www.novartis.com/newsroom/media-releases/en/2014/1816270.shtml
  
  uly 07, 2014 18:30 CET
  
  View all media releases
  
  Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation
  
  Designation supports the advancement of CTL019 to help address the unmet need of patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL)
  
  The filing was submitted by the University of Pennsylvania's Perelman School of Medicine which is conducting the CTL019 Phase I/II clinical trials
  
  Novartis and Penn have exclusive global collaboration to research, develop and commercialize CAR T cell therapies for the investigational treatment of cancers
- - September 20, 2014 at 3:46 pm
  - Quote
  JerryfromFauq
  Participant
  http://www.novartis.com/newsroom/media-releases/en/2014/1816270.shtml
  
  uly 07, 2014 18:30 CET
  
  View all media releases
  
  Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation
  
  Designation supports the advancement of CTL019 to help address the unmet need of patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL)
  
  The filing was submitted by the University of Pennsylvania's Perelman School of Medicine which is conducting the CTL019 Phase I/II clinical trials
  
  Novartis and Penn have exclusive global collaboration to research, develop and commercialize CAR T cell therapies for the investigational treatment of cancers
- - September 20, 2014 at 3:46 pm
  - Quote
  JerryfromFauq
  Participant
  http://www.novartis.com/newsroom/media-releases/en/2014/1816270.shtml
  
  uly 07, 2014 18:30 CET
  
  View all media releases
  
  Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation
  
  Designation supports the advancement of CTL019 to help address the unmet need of patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL)
  
  The filing was submitted by the University of Pennsylvania's Perelman School of Medicine which is conducting the CTL019 Phase I/II clinical trials
  
  Novartis and Penn have exclusive global collaboration to research, develop and commercialize CAR T cell therapies for the investigational treatment of cancers
- - September 21, 2014 at 11:16 pm
  - Quote
  RJoeyB
  Participant
  Jualonso,
  
  Further down this thread:
  
  http://www.melanoma.org/find-support/patient-community/mpip-melanoma-patients-information-page/are-engineered-virus-going-be
  
  is some discussion of the CAR T-cell approach (CTL019) being taken with leukemia (and now other cancers, including melanoma) by Dr. Carl June at Penn (and elsewhere now). A disabled HIV virus is used to invade and genetically modify a patient's T-cells ex-vivo, where they are then multiplied and reinfused to the patient, similar to TIL.
  
  Exciting work with some dramatic (and rapid) responses in some leukemia patients who were out of options.
  
  Joe
  - September 23, 2014 at 3:44 pm
    
    Quote
    Mat
    Participant
    
    Joe, I attended Penn's melanoma conference in May and, at that time, they anticipated starting this trial (i.e., accepting the first patient) later this year. Not sure if the timeline has moved, but I'll ask Dr. Schuchter about it at my next appt.
  - September 23, 2014 at 3:44 pm
    
    Quote
    Mat
    Participant
    
    Joe, I attended Penn's melanoma conference in May and, at that time, they anticipated starting this trial (i.e., accepting the first patient) later this year. Not sure if the timeline has moved, but I'll ask Dr. Schuchter about it at my next appt.
  - September 23, 2014 at 3:44 pm
    
    Quote
    Mat
    Participant
    
    Joe, I attended Penn's melanoma conference in May and, at that time, they anticipated starting this trial (i.e., accepting the first patient) later this year. Not sure if the timeline has moved, but I'll ask Dr. Schuchter about it at my next appt.
- - September 21, 2014 at 11:16 pm
  - Quote
  RJoeyB
  Participant
  Jualonso,
  
  Further down this thread:
  
  http://www.melanoma.org/find-support/patient-community/mpip-melanoma-patients-information-page/are-engineered-virus-going-be
  
  is some discussion of the CAR T-cell approach (CTL019) being taken with leukemia (and now other cancers, including melanoma) by Dr. Carl June at Penn (and elsewhere now). A disabled HIV virus is used to invade and genetically modify a patient's T-cells ex-vivo, where they are then multiplied and reinfused to the patient, similar to TIL.
  
  Exciting work with some dramatic (and rapid) responses in some leukemia patients who were out of options.
  
  Joe
- - September 21, 2014 at 11:16 pm
  - Quote
  RJoeyB
  Participant
  Jualonso,
  
  Further down this thread:
  
  http://www.melanoma.org/find-support/patient-community/mpip-melanoma-patients-information-page/are-engineered-virus-going-be
  
  is some discussion of the CAR T-cell approach (CTL019) being taken with leukemia (and now other cancers, including melanoma) by Dr. Carl June at Penn (and elsewhere now). A disabled HIV virus is used to invade and genetically modify a patient's T-cells ex-vivo, where they are then multiplied and reinfused to the patient, similar to TIL.
  
  Exciting work with some dramatic (and rapid) responses in some leukemia patients who were out of options.
  
  Joe

Viewing 14 reply threads

You must be logged in to reply to this topic.

Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation

Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation

Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation

About the MRF Patient Forum

Popular Topics

do you know this treatment, CAR t cells?

Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation

Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation

Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation

About the MRF Patient Forum

Popular Topics

Topic Tags